It's really cumbersome to deal with such a project.

Zhang Chen thought about it and decided that it would be better to leave this kind of thing to "Commander No. 1" in the future.

He just wants to learn the system quietly.

Zhang Chen secretly made up his mind in his heart, but for now, it was better to handle this matter himself.

So, he called Huang Ruifang and Liu Qiang to the office again.

Compared with life-extending products, Zhang Chen is more confident in the research and development of oncolytic virus drugs.

Overall, the development of this drug is relatively simple.

His principle is not even as complex as gene therapy.

In addition, with the experience of R&D of the drug Lanyue 001.

Zhang Chen believes that in a few months, oncolytic virus drugs for the treatment of stomach cancer and lung cancer will be on the market.

Moreover, Huang Ruifang and Liu Qiang are still veterans in this field, and they will definitely be able to ensure the progress of research and development.

"Both, I have done a lot of research on oncolytic viruses before, and some relevant information has been sent to your work mailbox, if you have time, you can learn a little about it, and we can discuss it at any time if we have questions."

Zhang Chen motioned for the two to sit down, and then said step by step.

He thought in his heart that the research and development of drugs should not be too anxious, this is a major matter of human life.

If it is a daily necessities like shampoo, it can speed up the research and development a little.

Moreover, Huang Ruifang and Liu Qiang have just come to the company, and some work things need to be run in for a while.

Now that there is no gene therapy project for the time being, Zhang Chen wants to ask Tian Wenbin and Jiang Lu to help them get oncolytic viruses.

The cooperation between several people also requires a certain amount of running-in time.

Huang Ruifang and Liu Qiang were not too surprised by Zhang Chen's sudden oncolytic virus information.

They had already done a good job of psychological construction, and even felt that Zhang Chen had no technical reserves, so something was wrong.

Although Chenyue Biology had never been involved in oncolytic viruses on the surface, Zhang Chen still recruited the two of them without hesitation.

Moreover, after they joined the company, they immediately set up the project, and a large amount of R&D funds were directly allocated to the project team.

If he didn't have some confidence, how could Zhang Chen do this.

Thinking of this, Huang Ruifang smiled and nodded, "Mr. Zhang, rest assured, although we have just arrived, the speed of getting started will not be too slow, these two therapeutic targets are both fields that we are very familiar with." ”

Liu Qiang on the side immediately took over.

"Well, coupled with our company's high-quality sequencing and experimental animals, I think the progress of the whole project will definitely be very fast, when Beihe Gene, our project got the final results three months ahead of schedule, just ......"

Liu Qiang unconsciously mentioned the previous project, and after reacting, he suddenly felt a little embarrassed.

I'm afraid that the air will suddenly be quiet.

At this time, Zhang Chen hurried to the rescue, and he handed the oncolytic virus information printed out in his hand to the two of them.

Then he said: "Liu Bo is right, our company has incomparable advantages, and now there is an accurate detection equipment missing, I am preparing, and I plan to get the mass spectrometer done." ”

Huang Ruifang and the others had a preconceived idea that Zhang Chen just wanted to buy a mass spectrometer, so they didn't ask much.

Ten times their imagination, Zhang Chen wanted to mass-produce mass spectrometers.

The mass spectrometers on the market are now more than 10 million, close to 20 million.

In the eyes of Huang Ruifang and the others, even if they buy ten or eight units, it is not a problem for Zhang Chen at all.

With a mass spectrometer, it is indeed more convenient to do various detection experiments, and the experimental results obtained will be more accurate and precise.

The two of them immediately began to look at the information in their hands.

Oncolytic virus therapy generally uses adenovirus as the delivery vehicle.

Adenovirus has certain advantages over other delivery vectors, and it has high genetic stability.

It is also less pathogenic, and even if it is a wild-type adenovirus, it is not a big threat to humans after infection.

In addition, they are relatively easy to produce, producing high viral titers and purity.

The production process of adenovirus has been developed to perfection.

Therefore, it not only plays a vital role in oncolytic virus therapy.

Adenoviruses can also be found in various other fields, such as gene therapy and vaccine development.

Lanyue 001 is to use adeno-associated virus as a delivery carrier.

The modified oncolytic adenovirus became a conditioned replicating adenovirus.

It can replicate relatively specifically in various tumor cells, can lyse tumor cells, and at the same time release progeny viruses, and then infect other surrounding tumor cells.

And through the cascade amplification effect, the tumor is completely eliminated, so as to obtain a perfect curative effect.

The two oncolytic adenoviruses produced by the system are more specific.

They do not infect normal non-cancerous cells, and normal normal cells are not affected at all.

But once they encounter tumor cells, they become immediately infected, initiating self-replication after infection, eventually producing more viral progeny and ultimately inducing immunogenic cell death.

After cell lysis, viral progeny, pathogen-associated molecules, damage-associated molecules, and tumor-associated antigens are all released into the tumor microenvironment.

The released viral offspring further infect uninfected tumor cells and continue to spread the virus to kill cancer cells.

In addition, immunostimulatory molecules released into the tumor microenvironment attract immune cells to the tumor at the same time, triggering both innate and adaptive immunity to the tumor.

Don't underestimate the body's natural immune system, they are even more effective than these foreign therapeutic factors.

However, tumor cells have various immune escape mechanisms.

In general, the innate immune system does not work on tumor cells.

Immunostimulatory molecules act as a catalyst that can make the immune escape of tumor cells fail.

The two products produced by the system will definitely not only have these advantages.

A few minutes later, Huang Ruifang couldn't help but sigh softly.

"Any questions?" Zhang Chen asked.

"Mr. Zhang, are you sure that these two oncolytic virus products are administered intravenously?"

Huang Ruifang was a little surprised that oncolytic virus therapy can basically only be administered by intratumoral injection.

As the name suggests, this method of administration is to inject the drug directly into the tumor.

It needs to be used in conjunction with surgery to administer the drug.

If it is a brain tumor, a craniotomy is also required.

This is also the biggest defect of oncolytic virus therapy, but this defect does not seem to exist in Zhang Chen.

The information is clearly written that these two products have been administered intravenously.

Huang Ruifang couldn't understand how Zhang Chen did it?

Intratumoral injection is due to the nature of the oncolytic adenovirus.

Although it is specific, its specificity is not strong.

In other words, if it is injected intravenously, it will inevitably cause irreversible damage to ordinary cells.

Therefore, it can only be injected intratumorally to reduce the damage to normal cells.

Another reason is that oncolytic adenovirus is not very mobile, and after intravenous administration, it is likely that it will not be delivered to the location of the lesion.

This will not work as well as it should, but will damage a large number of normal cells.